Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HRAS | P01112 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866936 | 0.87 | NPC1 (0.44) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4866845 | 0.86 | NPC1 (0.43) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4532055 | 0.86 | NPC1 (0.43) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4864488 | 0.84 | EPHX2 (0.40) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4864498 | 0.84 | EPHX2 (0.40) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4867430 | 0.82 | LMNA (0.50) | NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL4870442 | 0.82 | EPHX2 (0.39) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4870434 | 0.82 | EPHX2 (0.39) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL4866087 | 0.78 | EPHX2 (0.45) | NPC1RAB9AEPHX2ALDH1A1HRAS | |
| SCHEMBL6237661 | 0.78 | EPHX2 (0.45) | NPC1RAB9AEPHX2ALDH1A1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | NPC1 1328/4885RAB9A 2101/4885EPHX2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.